<DOC>
	<DOCNO>NCT00234039</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving gemcitabine directly bladder may kill tumor cell . PURPOSE : This phase II trial study well gemcitabine work treat patient recurrent bladder cancer progress despite previous Bacillus Calmette-Guerin ( BCG ) .</brief_summary>
	<brief_title>S0353 , Gemcitabine Treating Patients With Recurrent Bladder Cancer That Has Not Responded Previous Bacillus Calmette-Guerin</brief_title>
	<detailed_description>OBJECTIVES : - Determine 8-12 week efficacy intravesical gemcitabine , term complete response rate , patient recurrent superficial transitional cell carcinoma bladder progress despite prior intravesical Bacillus Calmette-Guerin ( BCG ) . - Determine recurrence-free , worsening-free , progression-free , overall survival patient treated drug . - Evaluate toxicity drug patient . - Correlate , preliminarily , expression level gene genetic polymorphism involve gemcitabine pathway angiogenesis clinical toxicity , response , relapse-free survival patient treated drug . OUTLINE : This multicenter study . - Induction therapy : Patients receive gemcitabine intravesically week 6 week ( week 1-6 ) absence disease progression unacceptable toxicity . Patients achieve complete response proceed maintenance therapy week 14 . - Maintenance therapy : Patients receive gemcitabine intravesically week 14 , 18 , 22 , 26 , 30 , 34 , 38 , 42 , 46 , 50 absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 25-45 patient accrue study within 6-12 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm superficial transitional cell carcinoma ( TCC ) bladder meet 1 follow stage criterion : Stage T1 , grade 23 Stage Tis Stage Ta , grade 34 multifocal ( &gt; 2 lesion ) Must receive fail ≥ 2 course intravesical Bacillus CalmetteGuerin ( BCG ) ( one 6week course , plus one 3week course , few week BCG discontinue due side effect ) within past 3 year Recurrent disease Must transurethral resection bladder tumor ( TURBT ) bladder biopsy within past 60 day document tumor recurrence tumor stage grade TURBT biopsy must perform ≥ 6 week completion BCG and/or immunotherapy treatment ( ≥ 14 day completion intravesical chemotherapy treatment ) All visible tumor must resect time last biopsy No evidence urethral renal pelvis TCC upper tract radiological imaging ( e.g. , intravenous pyelogram , CT urogram , retrograde pyelogram ) within past 2 year PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Prior intravesical interferon alfa allow , alone combination Bacillus CalmetteGuerin ( BCG ) Chemotherapy See Disease Characteristics No 1 course intravesical chemotherapy ( e.g. , thiotepa , mitomycin , doxorubicin ) within past year , define 6 weekly instillation , without monthly maintenance instillation No prior gemcitabine Endocrine therapy Not specify Radiotherapy No prior pelvic radiotherapy No concurrent radiotherapy area body Surgery See Disease Characteristics Recovered prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>